Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to Strong-Buy Rating

by · The Cerbat Gem

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Read Our Latest Stock Analysis on SUPN

Supernus Pharmaceuticals Trading Down 1.0 %

Shares of Supernus Pharmaceuticals stock opened at $32.49 on Tuesday. The firm has a market capitalization of $1.81 billion, a PE ratio of 30.36 and a beta of 0.84. The firm’s 50 day moving average is $34.68 and its 200 day moving average is $35.03. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock worth $440,263. Insiders own 9.30% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SUPN. Vident Advisory LLC raised its holdings in Supernus Pharmaceuticals by 2.2% during the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after purchasing an additional 309 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in Supernus Pharmaceuticals by 7.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after buying an additional 369 shares during the last quarter. Bank of Montreal Can lifted its holdings in Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 473 shares during the period. Exchange Traded Concepts LLC boosted its position in Supernus Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in Supernus Pharmaceuticals by 7.3% during the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after acquiring an additional 624 shares during the period.

Supernus Pharmaceuticals Company Profile

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Read More